HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction

Introduction A quarter of breast cancers show human epidermal growth factor-2 (HER2) overexpression, where targeted therapy dramatically improves survival. However, cancer therapy-related cardiac dysfunction (CTRCD) occurs in up to 15% of patients. With the interruption of HER2 therapy, if necessary...

Descripció completa

Dades bibliogràfiques

Autors principals:	Robin Chung, James C Moon, Alexander R Lyon, Charlotte H Manisty, Muhummad Sohaib Nazir, Malcolm Walker, Peter Kellman, Benjamin Dowsing, Daniel Chen, Jessica Artico, Mark Westwood, Hakim-Moulay Dehbi, Rebecca Roylance, Tom Crake, Peter Schmid, Arjun Ghosh, Maria Sol Andres, Joanna Pedra, Orla Worn
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2025-02-01
Col·lecció:	BMJ Open
Accés en línia:	https://bmjopen.bmj.com/content/15/2/e091917.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!